Sekar Kathiresan - Dec 27, 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Dec 27, 2021
Transactions value $
-$1,887,851
Form type
4
Date filed
12/29/2021, 03:38 PM
Previous filing
Dec 27, 2021
Next filing
Jan 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $58.4K +42K +10.33% $1.39* 449K Dec 27, 2021 Direct
transaction VERV Common Stock Sale -$1.46M -36.4K -8.12% $40.02 412K Dec 27, 2021 Direct F1, F2
transaction VERV Common Stock Sale -$197K -4.79K -1.16% $41.24 407K Dec 27, 2021 Direct F1, F3
transaction VERV Common Stock Sale -$32.5K -770 -0.19% $42.21 407K Dec 27, 2021 Direct F1, F4
transaction VERV Common Stock Options Exercise $9.3K +6.69K +1.65% $1.39* 413K Dec 28, 2021 Direct
transaction VERV Common Stock Sale -$267K -6.69K -1.62% $39.90 407K Dec 28, 2021 Direct F1
holding VERV Common Stock 81K Dec 27, 2021 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 81K Dec 27, 2021 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -42K -13.21% $0.00 276K Dec 27, 2021 Common Stock 42K $1.39 Direct F5
transaction VERV Stock Option (right to buy) Options Exercise $0 -6.69K -2.43% $0.00 269K Dec 28, 2021 Common Stock 6.69K $1.39 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.86 to $41.74, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.84 to $42.49, inclusive.
F5 The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.